Please login to the form below

Not currently logged in
Email:
Password:

GSK trials shingles vaccine

GlaxoSmithKline has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles

GlaxoSmithKline (GSK) has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles.

The phase III clinical programme will study more than 30,000 patients worldwide and will evaluate the efficacy, safety and immunogenicity of the vaccine.

Norman Begg, chief medical officer of GSK Biologicals said: "The commencement of the phase III programme for our candidate's herpes zoster vaccine is a significant milestone. Shingles is an often debilitating condition for which there are limited treatment and prevention options.

"Progression into late-stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need," he added.

Herpes zoster is commonly known as shingles. It is caused by the varicella-zoster virus (VZV) and occurs in around 3 out of 1,000 people per year in Europe.

24th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....